Abstract
The common patatin-like phospholipase domain-containing protein 3 (PNPLA3) variant I148M predisposes to nonalcoholic liver disease but not its metabolic sequelae. We compared the handling of labeled polyunsaturated fatty acids (PUFAs) and saturated fatty acids (SFA) in vivo in humans and in cells harboring different PNPLA3 genotypes. In 148M homozygous individuals, triglycerides (TGs) in very low-density lipoproteins (VLDL) were depleted of PUFAs both under fasting and postprandial conditions compared with 148I homozygotes, and the PUFA/SFA ratio in VLDL-TGs was lower relative to the chylomicron precursor pool. In human PNPLA3-148M and PNPLA3-KO cells, PUFA but not SFA incorporation into TGs was increased at the expense of phosphatidylcholines, and under lipolytic conditions, PUFA-containing diacylglycerols (DAGs) accumulated compared with PNPLA3-148I cells. Polyunsaturated TGs were increased, while phosphatidylcholines (PCs) were decreased in the human liver in 148M homozygous individuals as compared with 148I homozygotes. We conclude that human PNPLA3-I148M is a loss-of-function allele that remodels liver TGs in a polyunsaturated direction by impairing hydrolysis/transacylation of PUFAs from DAGs to feed phosphatidylcholine synthesis.
| Original language | English |
|---|---|
| Article number | 127902 |
| Journal | JCI Insight |
| Volume | 4 |
| Issue number | 16 |
| DOIs | |
| Publication status | Published - 22 Aug 2019 |
| MoE publication type | A1 Journal article-refereed |
Funding
1Minerva Foundation Institute for Medical Research, Helsinki, Finland. 2Department of Medicine, University of Helsinki We thank Anne Salo, Aila Karioja-Kallio, Päivi Ihamuotila, and Pentti Pölönen for their excellent technical assistance; Siiri Luukkonen for graphical assistance; Shiqian Li for his generous help in designing A431 CRISPR cell lines; and the volunteers for their help. This study was supported by research grants from the Academy of Finland (HY grant 309263 and E. Ikonen grants 282192, 307415, 312491), EU H2020 project Elucidating Pathways of Steatohepatitis (HY EPoS grant 634413), and the H2020-JTI-IMI2 EU project 777377-2 Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) (HY), as well as from EVO (HY), Paulo (PKL), Sigrid Juselius (HY, PKL, E. Ikonen), Finnish Medical (PKL), Alfred Kordelin (PKL), and Liv och Hälsa (MH-V) foundations.